Enter at least 3 characters

HOME > Press releases
 

PRESS RELEASES

Chiesi Group's 2023 revenue surpasses €3 billion mark, reflecting 10% growth year-on-year (+12% @CER), underlining commitment to innovative, sustainable practices
23 April 2024
Chiesi’s carbon minimal inhalers reach innovation milestone as phase III trials now underway
04 April 2024
Chiesi named one of the UK’s Best Workplaces™ 2024
28 March 2024
Chiesi Group announces the passing of Honorary President Dr. Paolo Chiesi (1940-2024)
07 March 2024
Chiesi announces carbon neutral respiratory portfolio
14 Feburary 2024
Chiesi recognised as a Top Employer in United Kingdom for 13th consecutive year
18 January 2024
Chiesi Group and Oak Hill Bio announce License and Development Agreement to develop, manufacture, and commercialise OHB-607, a potentially transformative neonatal therapy
10 January 2024
Chiesi named as a Great Place to Work-Certified™ Company
23 November 2023
Chiesi Group signed a License Agreement with Haisco Pharmaceutical to develop, manufacture, and commercialise a novel, reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis
20 November 2023
NICE recommends Lamzede®▼ (velmanase alfa) as first ever enzyme replacement therapy for initiation in children with alpha-mannosidosis in England and Wales in final evaluation document
09 November 2023
Chiesi Limited announces new senior level changes to leadership team
30 October 2023
Chiesi global rare diseases releases report on the burden of care for rare diseases and its economic impact on European citizens
30 October 2023
Climate change threatens respiratory patients' quality of life stretching beyond physical health, new Economist report warns
07 September 2023
NICE recommends Elfabrio®▼(pegunigalsidase alfa) for adults with fabry disease in final draft guidance
01 September 2023
MHRA grants marketing authorisation for Elfabrio®▼(pegunigalsidase alfa) for the treatment of adult patients with fabry disease in Great Britain
16 August 2023
Chiesi Group mid-year financial results demonstrate strong growth 2023
04 August 2023
Chiesi recognised amongst UK’s Best Workplaces for Women for fourth consecutive year
20 July 2023
Chiesi global rare diseases announces FDA approval of Lamzede® (velmanase alfa-tycv)
16 March 2023
High strength Trimbow pMDI recommended for use within NHS Scotland
04 November 2022
Chiesi is recertified as a B Corp and sets new tougher objectives for action by 2025
04 November 2022
Chiesi and Aptar partner to bring to market disease management platform for patients with asthma and COPD
04 November 2022
Chiesi’s new carbon minimal pMDI propellant shows similar safety and tolerability profile as existing propellant
22 September 2022
Chiesi UK was officially named a 2022 UK’s Best Workplaces™ for Women for a third time!
29 July 2022
Chiesi Group calls for #ActionOverWords in the fight against climate change
10 May 2021
© 2024 Chiesi Limited
333 Styal Road Manchester M22 5LG
Registered in England and Wales No. 2140985. VAT Registration No. GB686750782
CHIESI ON THE WEB
FOLLOW US ON:
Details of Chiesi’s clinical trials can be found at www.clinicaltrials.gov
-